Section
Belzutifan demonstrates sustained tumor response and manageable safety over 50 months in patients with von Hippel-Lindau disease-associated renal cell carcinoma, supporting its role as a systemic therapy.
This study demonstrates that disitamab vedotin plus toripalimab significantly improves survival outcomes over chemotherapy in untreated HER2-positive advanced urothelial cancer.
Datroway combined with rilvegostomig demonstrates impressive tumor response and disease control in advanced urothelial carcinoma, heralding a new therapeutic option in first- and second-line settings.
A recent trial evaluates the effectiveness of counseling interventions on patient preparedness and sexual outcomes after pelvic surgeries.
A novel, evidence-based counseling tool was developed to guide patients in safely resuming sexual activity after pelvic reconstructive surgery. The tool integrates patient perspectives and expert input, addressing safety, discomfort, and re
The ESD 2025 expert consensus updates diagnosis, prevention and interventional care for urinary stones—prioritizing metabolic evaluation, morpho‑compositional stone analysis, pressure/temperature safety in endourology, suction-enabled RIRS,
This secondary analysis of the ARCHES trial demonstrates that enzalutamide plus ADT improves progression-free and overall survival in mHSPC patients across PSA levels, with undetectable PSA strongly predicting favorable outcomes.
A secondary analysis of the PROTECT trial reveals cribriform-positive prostate cancer significantly elevates 15-year metastasis risk, with radiotherapy plus neoadjuvant ADT reducing this risk more effectively than surgery or active monitori
Interim results from the phase 2 SunRISe-4 trial demonstrate that neoadjuvant TAR-200 combined with cetrelimab significantly improves pathological complete response rates versus cetrelimab alone in muscle-invasive bladder cancer patients in
A phase 2 trial demonstrates that carefully selected patients with oligometastatic clear-cell renal-cell carcinoma can achieve prolonged systemic therapy-free survival and favorable progression-free survival using metastasis-directed radiot
This systematic review and meta-analysis evaluates the effects of obesity interventions—lifestyle modification, pharmacotherapy, and bariatric surgery—on male fertility, highlighting improvements with lifestyle changes and limited benefits
This article reviews current evidence from a Cochrane systematic review on vaginal laser therapy for stress urinary incontinence in women, highlighting uncertain efficacy and safety profiles compared to sham and other treatments.
The PRIME trial demonstrates that biparametric MRI, omitting contrast enhancement, is noninferior to multiparametric MRI in detecting clinically significant prostate cancer, offering a faster, cost-effective alternative potentially transfor
This article reviews microsurgical techniques and patient outcomes in penile replantation, highlighting complications, innovative management strategies, and the critical need for standardized protocols to improve functional and aesthetic re
Despite proven survival benefit, nearly half of patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations did not receive PARP inhibitors in a US real-world study, highlighting critical gaps in treatment ac
A phase 2 randomized trial demonstrates that PSMA-PET-guided intensification of salvage radiotherapy after radical prostatectomy significantly improves failure-free survival without added toxicity.
The GROUQ-PCS 9 trial demonstrates that adding stereotactic body radiotherapy to standard androgen deprivation therapy and enzalutamide significantly prolongs radiographic progression-free survival in oligometastatic castration-resistant pr
A large Harvard study finds that frequent ejaculation—about 21 times a month—is associated with a significantly reduced risk of prostate cancer among men, offering new insights into modifiable factors for prevention.
The PEACE-3 trial demonstrates that adding radium-223 to enzalutamide significantly improves radiological progression-free survival and suggests an overall survival benefit in metastatic castration-resistant prostate cancer with bone metast
This phase 1 trial identifies 3.0 mg/kg as the optimal safe and effective dose of rizedisben, a novel myelin-binding fluorophore, enhancing sustained intraoperative nerve fluorescence during robot-assisted laparoscopic radical prostatectomy
